Compare DGII & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | CDNA |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | DGII | CDNA |
|---|---|---|
| Price | $44.15 | $19.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $46.80 | $26.67 |
| AVG Volume (30 Days) | 295.4K | ★ 768.6K |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | N/A |
| EPS | 1.08 | ★ 1.22 |
| Revenue | ★ $430,221,000.00 | $357,998,000.00 |
| Revenue This Year | $10.51 | $14.11 |
| Revenue Next Year | $8.01 | $11.75 |
| P/E Ratio | $41.19 | ★ $16.03 |
| Revenue Growth | 1.46 | ★ 14.46 |
| 52 Week Low | $22.39 | $10.96 |
| 52 Week High | $48.00 | $25.95 |
| Indicator | DGII | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 54.88 |
| Support Level | $43.60 | $19.01 |
| Resistance Level | $44.59 | $20.61 |
| Average True Range (ATR) | 1.23 | 0.80 |
| MACD | -0.34 | -0.15 |
| Stochastic Oscillator | 18.64 | 25.75 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.